Angiographic, procedural variables and antithrombotic therapies administered in the cath lab in the two groups
| UDOAC n=72 | IDOAC n=60 | P value | |
| Radial approach, n (%) | 66 (91.7) | 55 (91.7) | 1.0 |
| Multivessel disease, n (%) | 29 (40.3) | 34 (56.7) | 0.06 |
| Site of PCI, n (%) | |||
| Left main | 6 (8.3) | 4 (6.7) | 0.76 |
| Left anterior descending | 39 (54.2) | 40 (66.7) | 0.14 |
| Circumflex | 18 (25.0) | 15 (25.0) | 1.0 |
| Ramus intermedius | 7 (9.7) | 2 (3.3) | 0.18 |
| Right coronary artery | 26 (36.1) | 17 (28.3) | 0.34 |
| Arterial/venous graft | 2 (2.8) | 2 (3.3) | 1.0 |
| DES, n (%) | 72 (100) | 57 (95) | 0.09 |
| Stents implanted/patient, median (IQR) | 1 (1–2) | 2 (1–2) | 0.39 |
| GP IIb/IIIa inhibitors, n (%) | 4 (5.6) | 0 | 0.13 |
| Unfractionated heparin, n (%) | 42 (58.3) | 45 (75.0) | 0.04 |
BMS, bare metal stent; DES, drug-eluting stent; GP IIb/IIIa, glycoprotein IIb/IIIa receptor inhibitors; IDOAC, interrupted direct oral anticoagulant; PCI, percutaneous coronary intervention; UDOAC, uninterrupted direct oral anticoagulant.